Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07204418) titled 'A Study to Evaluate the Effects of CYP2D6 Phenotypes on the Pharmacokinetics of Xanomeline Following KarXT Administration in Healthy Adult Participants' on Sept. 24.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Karuna Therapeutics
Condition:
Healthy Volunteers
Intervention:
Drug: Xanomeline/ Trospium Chloride
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: October 14, 2025
Target Sample Size: 56
Countries of Recruitment:
United States
To know more, ...